Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Erratum to: Diagnosis and treatment based on quantitative PCR after controlled human malaria infection.

Walk J, Schats R, Langenberg MC, Reuling IJ, Teelen K, Roestenberg M, Hermsen CC, Visser LG, Sauerwein RW.

Malar J. 2016 Oct 28;15(1):522. No abstract available.

2.

Diagnosis and treatment based on quantitative PCR after controlled human malaria infection.

Walk J, Schats R, Langenberg MC, Reuling IJ, Teelen K, Roestenberg M, Hermsen CC, Visser LG, Sauerwein RW.

Malar J. 2016 Aug 5;15(1):398. doi: 10.1186/s12936-016-1434-z. Erratum in: Malar J. 2016 Oct 28;15(1):522.

3.

Impact of malaria preexposure on antiparasite cellular and humoral immune responses after controlled human malaria infection.

Obiero JM, Shekalaghe S, Hermsen CC, Mpina M, Bijker EM, Roestenberg M, Teelen K, Billingsley PF, Sim BK, James ER, Daubenberger CA, Hoffman SL, Abdulla S, Sauerwein RW, Scholzen A.

Infect Immun. 2015 May;83(5):2185-96. doi: 10.1128/IAI.03069-14. Epub 2015 Mar 16.

4.

Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial.

Bijker EM, Schats R, Obiero JM, Behet MC, van Gemert GJ, van de Vegte-Bolmer M, Graumans W, van Lieshout L, Bastiaens GJ, Teelen K, Hermsen CC, Scholzen A, Visser LG, Sauerwein RW.

PLoS One. 2014 Nov 14;9(11):e112910. doi: 10.1371/journal.pone.0112910. eCollection 2014.

5.

External quality assurance of malaria nucleic acid testing for clinical trials and eradication surveillance.

Murphy SC, Hermsen CC, Douglas AD, Edwards NJ, Petersen I, Fahle GA, Adams M, Berry AA, Billman ZP, Gilbert SC, Laurens MB, Leroy O, Lyke KE, Plowe CV, Seilie AM, Strauss KA, Teelen K, Hill AV, Sauerwein RW.

PLoS One. 2014 May 16;9(5):e97398. doi: 10.1371/journal.pone.0097398. eCollection 2014.

6.

Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis.

Felgner PL, Roestenberg M, Liang L, Hung C, Jain A, Pablo J, Nakajima-Sasaki R, Molina D, Teelen K, Hermsen CC, Sauerwein R.

Sci Rep. 2013 Dec 19;3:3549. doi: 10.1038/srep03549. Erratum in: Sci Rep. 2014;4:4151.

7.

Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity.

Bijker EM, Bastiaens GJ, Teirlinck AC, van Gemert GJ, Graumans W, van de Vegte-Bolmer M, Siebelink-Stoter R, Arens T, Teelen K, Nahrendorf W, Remarque EJ, Roeffen W, Jansens A, Zimmerman D, Vos M, van Schaijk BC, Wiersma J, van der Ven AJ, de Mast Q, van Lieshout L, Verweij JJ, Hermsen CC, Scholzen A, Sauerwein RW.

Proc Natl Acad Sci U S A. 2013 May 7;110(19):7862-7. doi: 10.1073/pnas.1220360110. Epub 2013 Apr 18.

8.

NF135.C10: a new Plasmodium falciparum clone for controlled human malaria infections.

Teirlinck AC, Roestenberg M, van de Vegte-Bolmer M, Scholzen A, Heinrichs MJ, Siebelink-Stoter R, Graumans W, van Gemert GJ, Teelen K, Vos MW, Nganou-Makamdop K, Borrmann S, Rozier YP, Erkens MA, Luty AJ, Hermsen CC, Sim BK, van Lieshout L, Hoffman SL, Visser LG, Sauerwein RW.

J Infect Dis. 2013 Feb 15;207(4):656-60. doi: 10.1093/infdis/jis725. Epub 2012 Nov 27.

9.

Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites.

Roestenberg M, Bijker EM, Sim BK, Billingsley PF, James ER, Bastiaens GJ, Teirlinck AC, Scholzen A, Teelen K, Arens T, van der Ven AJ, Gunasekera A, Chakravarty S, Velmurugan S, Hermsen CC, Sauerwein RW, Hoffman SL.

Am J Trop Med Hyg. 2013 Jan;88(1):5-13. doi: 10.4269/ajtmh.2012.12-0613. Epub 2012 Nov 13.

10.

Filter paper collection of Plasmodium falciparum mRNA for detecting low-density gametocytes.

Jones S, Sutherland CJ, Hermsen C, Arens T, Teelen K, Hallett R, Corran P, van der Vegte-Bolmer M, Sauerwein R, Drakeley CJ, Bousema T.

Malar J. 2012 Aug 8;11:266. doi: 10.1186/1475-2875-11-266.

11.

A cluster-randomized trial of mass drug administration with a gametocytocidal drug combination to interrupt malaria transmission in a low endemic area in Tanzania.

Shekalaghe SA, Drakeley C, van den Bosch S, ter Braak R, van den Bijllaardt W, Mwanziva C, Semvua S, Masokoto A, Mosha F, Teelen K, Hermsen R, Okell L, Gosling R, Sauerwein R, Bousema T.

Malar J. 2011 Aug 24;10:247. doi: 10.1186/1475-2875-10-247.

12.

Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study.

Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW.

Lancet. 2011 May 21;377(9779):1770-6. doi: 10.1016/S0140-6736(11)60360-7. Epub 2011 Apr 22.

PMID:
21514658
13.

Protection against a malaria challenge by sporozoite inoculation.

Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, RĂ©nia L, van der Ven A, Hermsen CC, Sauerwein R.

N Engl J Med. 2009 Jul 30;361(5):468-77. doi: 10.1056/NEJMoa0805832.

14.

Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

Roestenberg M, Remarque E, de Jonge E, Hermsen R, Blythman H, Leroy O, Imoukhuede E, Jepsen S, Ofori-Anyinam O, Faber B, Kocken CH, Arnold M, Walraven V, Teelen K, Roeffen W, de Mast Q, Ballou WR, Cohen J, Dubois MC, Ascarateil S, van der Ven A, Thomas A, Sauerwein R.

PLoS One. 2008;3(12):e3960. doi: 10.1371/journal.pone.0003960. Epub 2008 Dec 18.

15.

Epitope analysis of the malaria surface antigen pfs48/45 identifies a subdomain that elicits transmission blocking antibodies.

Outchkourov N, Vermunt A, Jansen J, Kaan A, Roeffen W, Teelen K, Lasonder E, Braks A, van de Vegte-Bolmer M, Qiu LY, Sauerwein R, Stunnenberg HG.

J Biol Chem. 2007 Jun 8;282(23):17148-56. Epub 2007 Apr 9.

16.

Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.

Hermsen CC, Verhage DF, Telgt DS, Teelen K, Bousema JT, Roestenberg M, Bolad A, Berzins K, Corradin G, Leroy O, Theisen M, Sauerwein RW.

Vaccine. 2007 Apr 12;25(15):2930-40. Epub 2006 Aug 2.

PMID:
16914240
17.

Transmission-reducing immunity is inversely related to age in Plasmodium falciparum gametocyte carriers.

Drakeley CJ, Bousema JT, Akim NI, Teelen K, Roeffen W, Lensen AH, Bolmer M, Eling W, Sauerwein RW.

Parasite Immunol. 2006 May;28(5):185-90.

18.

Rapid onset of transmission-reducing antibodies in javanese migrants exposed to malaria in papua, indonesia.

Bousema JT, Roeffen W, van der Kolk M, de Vlas SJ, van de Vegte-Bolmer M, Bangs MJ, Teelen K, Kurniawan L, Maguire JD, Baird JK, Sauerwein RW.

Am J Trop Med Hyg. 2006 Mar;74(3):425-31.

PMID:
16525101
19.

Parasite infectivity and immunity to Plasmodium falciparum gametocytes in Gambian children.

Drakeley CJ, Eling W, Teelen K, Bousema JT, Sauerwein R, Greenwood BM, Targett GA.

Parasite Immunol. 2004 Apr;26(4):159-65.

20.

Recombinant human antibodies specific for the Pfs48/45 protein of the malaria parasite Plasmodium falciparum.

Roeffen WF, Raats JM, Teelen K, Hoet RM, Eling WM, van Venrooij WJ, Sauerwein RW.

J Biol Chem. 2001 Jun 8;276(23):19807-11. Epub 2001 Feb 23.

Supplemental Content

Loading ...
Support Center